002437 誉衡药业
已收盘 11-09 15:00:00
资讯
新帖
简况
誉衡药业：11月4日独立董事徐宇虹增持股份合计1.02万股
证券之星 · 11-05
誉衡药业：11月4日独立董事徐宇虹增持股份合计1.02万股
誉衡药业：11月3日接受机构调研，杭州瀚石私募基金管理有限公司参与
证券之星 · 11-03
誉衡药业：11月3日接受机构调研，杭州瀚石私募基金管理有限公司参与
【机构调研记录】湘财基金调研仙琚制药、誉衡药业
证券之星 · 10-29
【机构调研记录】湘财基金调研仙琚制药、誉衡药业
图解誉衡药业三季报：第三季度单季净利润同比下降18.46%
证券之星 · 10-28
图解誉衡药业三季报：第三季度单季净利润同比下降18.46%
誉衡药业(002437.SZ)发布前三季度业绩，归母净利润2.48亿元，同比增长1.8%
智通财经 · 10-27
誉衡药业(002437.SZ)发布前三季度业绩，归母净利润2.48亿元，同比增长1.8%
誉衡药业(002437)9月30日股东户数17.57万户，较上期增加51.83%
证券之星 · 10-27
誉衡药业(002437)9月30日股东户数17.57万户，较上期增加51.83%
10月22日誉衡药业跌6.17%，中证2000ETF广发基金重仓该股
证券之星 · 10-22
10月22日誉衡药业跌6.17%，中证2000ETF广发基金重仓该股
10月19日誉衡药业跌7.65%，中证2000ETF广发基金重仓该股
证券之星 · 10-19
10月19日誉衡药业跌7.65%，中证2000ETF广发基金重仓该股
10月16日誉衡药业涨7.62%，中证2000ETF广发基金重仓该股
证券之星 · 10-16
10月16日誉衡药业涨7.62%，中证2000ETF广发基金重仓该股
异动快报：誉衡药业（002437）10月16日9点31分触及涨停板
证券之星 · 10-16
异动快报：誉衡药业（002437）10月16日9点31分触及涨停板
誉衡药业（002437）披露与首都医科大学签署《技术转让（专利权）合同》公告，10月15日股价下跌0.61%
证券之星 · 10-15
誉衡药业（002437）披露与首都医科大学签署《技术转让（专利权）合同》公告，10月15日股价下跌0.61%
誉衡药业(002437.SZ)拟受让取得《一种钙超载介导神经元死亡的标志物及应用》的专利权
智通财经 · 10-15
誉衡药业(002437.SZ)拟受让取得《一种钙超载介导神经元死亡的标志物及应用》的专利权
股市必读：誉衡药业新发布《董事会薪酬与考核委员会关于2024年限制性股票激励计划预留授予部分第二个限售期解除限售条件成就的核查意见》
证券之星 · 10-14
股市必读：誉衡药业新发布《董事会薪酬与考核委员会关于2024年限制性股票激励计划预留授予部分第二个限售期解除限售条件成就的核查意见》
10月12日誉衡药业跌7.32%，中证2000ETF广发基金重仓该股
证券之星 · 10-12
10月12日誉衡药业跌7.32%，中证2000ETF广发基金重仓该股
9月30日誉衡药业涨5.19%，中证2000ETF广发基金重仓该股
证券之星 · 09-30
9月30日誉衡药业涨5.19%，中证2000ETF广发基金重仓该股
股市必读：誉衡药业（002437）9月29日董秘有最新回复
证券之星 · 09-30
股市必读：誉衡药业（002437）9月29日董秘有最新回复
誉衡药业：公司2026年三季报披露日期为2026年10月28日
证券之星 · 09-29
誉衡药业：公司2026年三季报披露日期为2026年10月28日
誉衡药业：拟于10月28日披露2026年第三季度报告
证券之星 · 09-22
誉衡药业：拟于10月28日披露2026年第三季度报告
9月21日誉衡药业涨7.78%，中证2000ETF广发基金重仓该股
证券之星 · 09-21
9月21日誉衡药业涨7.78%，中证2000ETF广发基金重仓该股
股市必读：誉衡药业新发布《2026年第三次临时股东会法律意见书》
证券之星 · 09-14
股市必读：誉衡药业新发布《2026年第三次临时股东会法律意见书》
加载更多
公司概况
公司名称：
哈尔滨誉衡药业股份有限公司
所属行业：
医药制造业
上市日期：
2010-06-23
主营业务：
哈尔滨誉衡药业股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是维生素类药物、心脑血管药物、骨科药物、电解质类药物、抗肿瘤药物、抗感染药物、其他用药领域、糖尿病类药物、镇痛类药物。
发行价格：
50.00
{"stockData":{"symbol":"002437","market":"SZ","secType":"STK","nameCN":"誉衡药业","latestPrice":3.02,"timestamp":1794207801000,"preClose":2.99,"halted":0,"volume":100044616,"delay":0,"changeRate":0.01,"floatShares":2104000000,"shares":2229000000,"eps":0.1711,"marketStatus":"已收盘","change":0.03,"latestTime":"11-09 15:00:00","open":3.02,"high":3.05,"low":3,"amount":303000000,"amplitude":0.0167,"askPrice":3.02,"askSize":496,"bidPrice":3.01,"bidSize":26214,"shortable":0,"etf":0,"ttmEps":0.1711,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794274200000},"marketStatusCode":5,"adr":0,"adjPreClose":2.99,"symbolType":"stock","openAndCloseTimeList":[[1794187800000,1794195000000],[1794200400000,1794207600000]],"highLimit":3.29,"lowLimit":2.69,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":2229494326,"isCdr":false,"pbRate":2.6,"roa":"--","peRate":17.650497,"roe":"10.28%","epsLYR":0.1719,"committee":-0.034982,"marketValue":6733000000,"turnoverRate":0.0475,"status":0,"floatMarketCap":6356000000},"requestUrl":"/m/hq/s/002437","defaultTab":"news","newsList":[{"id":"2681073652","title":"誉衡药业：11月4日独立董事徐宇虹增持股份合计1.02万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2681073652","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681073652?lang=zh_cn&edition=full","pubTime":"2026-11-05 21:01","pubTimestamp":1793883683,"startTime":"0","endTime":"0","summary":"证券之星消息，根据11月5日市场公开信息、上市公司公告及交易所披露数据整理，誉衡药业（002437）最新董监高及相关人员股份变动情况：2026年11月4日公司独立董事徐宇虹共增持公司股份1.02万股，占公司总股本为0.0005%。变动期间公司股价上涨2.75%，11月4日当日收盘报2.99元。誉衡药业近半年内的董监高及核心技术人员增减持详情如下：誉衡药业的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流入20.1万，融资余额增加；融券净流入0.0，融券余额增加。该股最近90天内无机构评级。本文数据来源于深圳证券交易所信息披露、誉衡药业公告，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110500040798.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0095","BK0188","002437","BK0028","BK0239","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680672007","title":"誉衡药业：11月3日接受机构调研，杭州瀚石私募基金管理有限公司参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2680672007","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680672007?lang=zh_cn&edition=full","pubTime":"2026-11-03 23:04","pubTimestamp":1793718256,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年11月3日誉衡药业发布公告称公司于2026年11月3日接受机构调研，杭州瀚石私募基金管理有限公司参与。誉衡药业主营业务：从事药品的研发、生产和销售。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110300046303.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","002437","BK0060","BK0239","BK0095","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679445700","title":"【机构调研记录】湘财基金调研仙琚制药、誉衡药业","url":"https://stock-news.laohu8.com/highlight/detail?id=2679445700","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679445700?lang=zh_cn&edition=full","pubTime":"2026-10-29 08:16","pubTimestamp":1793233011,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及10月28日披露的机构调研信息，湘财基金近期对2家上市公司进行了调研，相关名单如下：1）仙琚制药 调研纪要：2026年前三季度收入29.28亿元，同比增长3.6%；净利润4.22亿元，同比增长3.82%。制剂销售基本持平，原料药增长10%。湘财基金成立于2018年，截至目前，资产管理规模57.25亿元；资产管理规模30.45亿元；管理公募基金数44只；旗下公募基金经理8人。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102900012478.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002332","BK0239","SG9999014674.SGD","002437","BK0077","BK0028","BK0060","BK0188","BK0095"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678104096","title":"图解誉衡药业三季报：第三季度单季净利润同比下降18.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678104096","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678104096?lang=zh_cn&edition=full","pubTime":"2026-10-28 00:58","pubTimestamp":1793120303,"startTime":"0","endTime":"0","summary":"证券之星消息，誉衡药业2026年三季报显示，前三季度公司主营收入14.27亿元，同比下降14.3%；归母净利润2.48亿元，同比上升1.8%；扣非净利润1.99亿元，同比上升11.74%；其中2026年第三季度，公司单季度主营收入4.2亿元，同比下降25.77%；单季度归母净利润8916.01万元，同比下降18.46%；单季度扣非净利润6869.98万元，同比下降3.93%；负债率23.63%，投资收益171.52万元，财务费用123.14万元，毛利率46.7%。财报数据概要请见下图:本文数据来源于誉衡药业2026年三季报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102800002478.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002437"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678176267","title":"誉衡药业(002437.SZ)发布前三季度业绩，归母净利润2.48亿元，同比增长1.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678176267","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678176267?lang=zh_cn&edition=full","pubTime":"2026-10-27 19:00","pubTimestamp":1793098849,"startTime":"0","endTime":"0","summary":"智通财经APP讯，誉衡药业(002437.SZ)发布2026年第三季度报告，公司前三季度实现营业收入14.27亿元，同比下降14.3%;归属于上市公司股东的净利润2.48亿元，同比增长1.8%;归属于上市公司股东的扣除非经常性损益的净利润1.99亿元，同比增长11.74%;基本每股收益0.1127元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1513486.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002437"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678758221","title":"誉衡药业(002437)9月30日股东户数17.57万户，较上期增加51.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678758221","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678758221?lang=zh_cn&edition=full","pubTime":"2026-10-27 18:43","pubTimestamp":1793097807,"startTime":"0","endTime":"0","summary":"证券之星消息，近日誉衡药业披露，截至2026年9月30日公司股东户数为17.57万户，较8月10日增加6.0万户，增幅为51.83%。在化学制药行业个股中，誉衡药业股东户数高于行业平均水平，截至9月30日，化学制药行业平均股东户数为3.84万户。从股价来看，2026年8月10日至2026年9月30日，誉衡药业区间涨幅为6.41%，在此期间股东户数增加6.0万户，增幅为51.83%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102700034885.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","BK0239","BK0077","002437","BK0060","BK0095"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677958150","title":"10月22日誉衡药业跌6.17%，中证2000ETF广发基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2677958150","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677958150?lang=zh_cn&edition=full","pubTime":"2026-10-22 16:45","pubTimestamp":1792658713,"startTime":"0","endTime":"0","summary":"证券之星消息，10月22日誉衡药业跌6.17%，收盘报3.04元，换手率11.51%，成交量242.27万手，成交额7.5亿元。重仓誉衡药业的公募基金请见下表：根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为广发基金的中证2000ETF广发。中证2000ETF广发目前规模为0.76亿元，最新净值1.3269，较上一交易日下跌0.32%，近一年下跌3.56%。中证2000ETF广发的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102200028665.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","002437","560220","BK0095","BK0239","BK0077","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676509659","title":"10月19日誉衡药业跌7.65%，中证2000ETF广发基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2676509659","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676509659?lang=zh_cn&edition=full","pubTime":"2026-10-19 16:33","pubTimestamp":1792398822,"startTime":"0","endTime":"0","summary":"证券之星消息，10月19日誉衡药业跌7.65%，收盘报3.26元，换手率20.17%，成交量424.02万手，成交额13.94亿元。重仓誉衡药业的公募基金请见下表：根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为广发基金的中证2000ETF广发。中证2000ETF广发目前规模为0.76亿元，最新净值1.3153，较上一交易日上涨0.3%，近一年下跌4.14%。中证2000ETF广发的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101900020470.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","560220","BK0188","BK0095","BK0239","BK0077","002437","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675562769","title":"10月16日誉衡药业涨7.62%，中证2000ETF广发基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2675562769","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675562769?lang=zh_cn&edition=full","pubTime":"2026-10-16 16:33","pubTimestamp":1792139596,"startTime":"0","endTime":"0","summary":"证券之星消息，10月16日誉衡药业涨7.62%，收盘报3.53元，换手率28.6%，成交量601.41万手，成交额21.35亿元。重仓誉衡药业的公募基金请见下表：根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为广发基金的中证2000ETF广发。中证2000ETF广发目前规模为0.76亿元，最新净值1.3114，较上一交易日下跌3.52%，近一年下跌5.53%。中证2000ETF广发的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101600027922.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002437","560220","BK0028","BK0060","BK0077","BK0095","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675554433","title":"异动快报：誉衡药业（002437）10月16日9点31分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2675554433","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675554433?lang=zh_cn&edition=full","pubTime":"2026-10-16 09:35","pubTimestamp":1792114554,"startTime":"0","endTime":"0","summary":"证券之星10月16日盘中消息，9点31分誉衡药业（002437）触及涨停板。其所属行业化学制药目前上涨。领涨股为N联亚。该股为基因测序，PD-1抑制剂，民营医院概念热股，当日基因测序概念上涨3.08%，PD-1抑制剂概念上涨3.04%，民营医院概念上涨1.94%。10月15日的资金流向数据方面，主力资金净流入4252.96万元，占总成交额4.8%，游资资金净流出166.94万元，占总成交额0.19%，散户资金净流出4086.02万元，占总成交额4.62%。近5日资金流向一览见下表：誉衡药业主要指标及行业内排名如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101600009968.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0060","002437","BK0095","BK0188","BK0239","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675653878","title":"誉衡药业（002437）披露与首都医科大学签署《技术转让（专利权）合同》公告，10月15日股价下跌0.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2675653878","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675653878?lang=zh_cn&edition=full","pubTime":"2026-10-15 22:08","pubTimestamp":1792073300,"startTime":"0","endTime":"0","summary":"截至2026年10月15日收盘，誉衡药业报收于3.28元，较前一交易日下跌0.61%，最新总市值为73.14亿元。该股当日开盘3.25元，最高3.5元，最低3.23元，成交额达8.85亿元，换手率为12.54%。近日，哈尔滨誉衡药业股份有限公司披露《关于与首都医科大学签署〈技术转让（专利权）合同〉的公告》。公告显示，公司与首都医科大学签署《技术转让（专利权）合同》，以1,115万元受让‘一种钙超载介导神经元死亡的标志物及应用’的专利权。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101500039296.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002437","BK0060","BK0077","BK0095","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675896015","title":"誉衡药业(002437.SZ)拟受让取得《一种钙超载介导神经元死亡的标志物及应用》的专利权","url":"https://stock-news.laohu8.com/highlight/detail?id=2675896015","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675896015?lang=zh_cn&edition=full","pubTime":"2026-10-15 19:14","pubTimestamp":1792062854,"startTime":"0","endTime":"0","summary":"智通财经APP讯，誉衡药业 发布公告，公司与首都医科大学签署《技术转让(专利权)合同》。根据《技术转让合同》约定，公司拟以1,115万元人民币的交易价格受让取得《一种钙超载介导神经元死亡的标志物及应用》的专利权。本项目涉及的“一种钙超载介导神经元死亡的标志物”是拟开发用于靶向TLK2的基因治疗疗法，有望切入“独立于降眼压的RGC神经保护” 这一未满足的临床需求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1507861.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"誉衡药业(002437.SZ)拟受让取得《一种钙超载介导神经元死亡的标志物及应用》的专利权","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0095","BK0077","002437","BK0060","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675369428","title":"股市必读：誉衡药业新发布《董事会薪酬与考核委员会关于2024年限制性股票激励计划预留授予部分第二个限售期解除限售条件成就的核查意见》","url":"https://stock-news.laohu8.com/highlight/detail?id=2675369428","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675369428?lang=zh_cn&edition=full","pubTime":"2026-10-14 01:48","pubTimestamp":1791913694,"startTime":"0","endTime":"0","summary":"公司公告汇总：誉衡药业审议通过2024年限制性股票激励计划预留授予部分第二个限售期解除限售事项，涉及35名激励对象、180万股限制性股票，占总股本0.0807%。公司公告汇总董事会薪酬与考核委员会关于2024年限制性股票激励计划预留授予部分第二个限售期解除限售条件成就的核查意见董事会薪酬与考核委员会确认35名激励对象解除限售资格合法有效，解除限售条件已全部成就，同意为其办理1,800,000股限制性股票解除限售事宜，并提交董事会审议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101400001632.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0095","BK0239","002437","BK0188","BK0077","BK0060","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674465878","title":"10月12日誉衡药业跌7.32%，中证2000ETF广发基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2674465878","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674465878?lang=zh_cn&edition=full","pubTime":"2026-10-12 16:44","pubTimestamp":1791794675,"startTime":"0","endTime":"0","summary":"证券之星消息，10月12日誉衡药业跌7.32%，收盘报3.42元，换手率13.19%，成交量277.27万手，成交额9.76亿元。重仓誉衡药业的公募基金请见下表：根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为广发基金的中证2000ETF广发。中证2000ETF广发目前规模为0.76亿元，最新净值1.4095，较上一交易日上涨0.04%，近一年上涨0.71%。中证2000ETF广发的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200021831.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0188","560220","BK0095","BK0239","BK0028","002437","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671426274","title":"9月30日誉衡药业涨5.19%，中证2000ETF广发基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2671426274","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671426274?lang=zh_cn&edition=full","pubTime":"2026-09-30 16:36","pubTimestamp":1790757404,"startTime":"0","endTime":"0","summary":"证券之星消息，9月30日誉衡药业涨5.19%，收盘报3.65元，换手率16.83%，成交量353.81万手，成交额12.77亿元。重仓誉衡药业的公募基金请见下表：根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为广发基金的中证2000ETF广发。中证2000ETF广发目前规模为0.76亿元，最新净值1.441，较上一交易日上涨0.97%，近一年上涨4.37%。中证2000ETF广发的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000025839.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","BK0239","BK0077","002437","560220","BK0060","BK0095"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671495362","title":"股市必读：誉衡药业（002437）9月29日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2671495362","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671495362?lang=zh_cn&edition=full","pubTime":"2026-09-30 01:05","pubTimestamp":1790701519,"startTime":"0","endTime":"0","summary":"截至2026年9月29日收盘，誉衡药业报收于3.47元，上涨0.58%，换手率9.05%，成交量190.19万手，成交额6.64亿元。董秘最新回复投资者： 董秘您好！董秘： 您好，公司2026年三季报披露日期为2026年10月28日，感谢关注！交易信息汇总资金流向9月29日主力资金净流入1106.31万元，占总成交额1.67%；游资资金净流入1809.36万元，占总成交额2.73%；散户资金净流出2915.67万元，占总成交额4.39%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000001678.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0060","002437","BK0188","BK0077","BK0095","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671294710","title":"誉衡药业：公司2026年三季报披露日期为2026年10月28日","url":"https://stock-news.laohu8.com/highlight/detail?id=2671294710","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671294710?lang=zh_cn&edition=full","pubTime":"2026-09-29 16:15","pubTimestamp":1790669715,"startTime":"0","endTime":"0","summary":"证券之星消息，誉衡药业(002437)09月29日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好！请问公司26年三季报什么时间披露？誉衡药业回复：您好，公司2026年三季报披露日期为2026年10月28日，感谢关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092900025113.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0060","002437","BK0095","BK0188","BK0239","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669700112","title":"誉衡药业：拟于10月28日披露2026年第三季度报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2669700112","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669700112?lang=zh_cn&edition=full","pubTime":"2026-09-22 16:27","pubTimestamp":1790065637,"startTime":"0","endTime":"0","summary":"证券之星消息，誉衡药业(002437)09月22日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好！请问公司26年三季报什么时间披露？誉衡药业回复：你好，公司拟于10月28日披露2026年第三季度报告，谢谢关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092200027638.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0060","BK0095","BK0239","BK0077","BK0188","002437"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669447159","title":"9月21日誉衡药业涨7.78%，中证2000ETF广发基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669447159","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669447159?lang=zh_cn&edition=full","pubTime":"2026-09-21 16:44","pubTimestamp":1789980298,"startTime":"0","endTime":"0","summary":"证券之星消息，9月21日誉衡药业涨7.78%，收盘报3.74元，换手率24.14%，成交量507.65万手，成交额18.68亿元。重仓誉衡药业的公募基金请见下表：根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为广发基金的中证2000ETF广发。中证2000ETF广发目前规模为0.76亿元，最新净值1.4595，较上一交易日上涨1.78%，近一年上涨4.9%。中证2000ETF广发的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100020985.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0060","002437","BK0077","560220","BK0239","BK0095","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667263827","title":"股市必读：誉衡药业新发布《2026年第三次临时股东会法律意见书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2667263827","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667263827?lang=zh_cn&edition=full","pubTime":"2026-09-14 04:07","pubTimestamp":1789330030,"startTime":"0","endTime":"0","summary":"公司公告汇总：誉衡药业2026年第三次临时股东大会审议通过续聘上会会计师事务所、修订公司章程及回购注销离职人员限制性股票三项议案，其中后两项为特别决议事项并获2/3以上表决权通过。公司公告汇总2026年第三次临时股东会法律意见书北京市京轩律师事务所出具法律意见书，认为哈尔滨誉衡药业股份有限公司2026年第三次临时股东大会的召集、召开程序符合相关法律法规及公司章程规定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091400001790.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","002437","BK0060","BK0095","BK0239","BK0077"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1794210705980,"stockEarnings":[{"period":"1week","weight":0.031},{"period":"1month","weight":-0.1808},{"period":"3month","weight":-0.0417},{"period":"6month","weight":-0.0994},{"period":"1year","weight":-0.1128},{"period":"ytd","weight":-0.0261}],"compareEarnings":[{"period":"1week","weight":0.0139},{"period":"1month","weight":-0.0502},{"period":"3month","weight":-0.0738},{"period":"6month","weight":-0.127},{"period":"1year","weight":-0.0895},{"period":"ytd","weight":-0.0805}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"哈尔滨誉衡药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"175662人(较上一季度增加51.83%)","perCapita":"11980股","listingDate":"2010-06-23","address":"黑龙江省哈尔滨市呼兰区利民经济技术开发区北京路29号","registeredCapital":"222949万元","survey":" 哈尔滨誉衡药业股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是维生素类药物、心脑血管药物、骨科药物、电解质类药物、抗肿瘤药物、抗感染药物、其他用药领域、糖尿病类药物、镇痛类药物。","listedPrice":50},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"誉衡药业(002437)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供誉衡药业(002437)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"誉衡药业,002437,誉衡药业股票,誉衡药业股票老虎,誉衡药业股票老虎国际,誉衡药业行情,誉衡药业股票行情,誉衡药业股价,誉衡药业股市,誉衡药业股票价格,誉衡药业股票交易,誉衡药业股票购买,誉衡药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"誉衡药业(002437)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供誉衡药业(002437)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}